Regorafenib inhibits angiogenesis and induces apoptosis.

Slides:

Advertisements

Similar presentations

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

Advertisements

Activation of EphB4 by ephrinB2‐Fc prevents aberrant angiogenesis

AG-221 induces the differentiation of IDH2R140Q blasts along myeloid lineages in primary human AML xenograft models. AG-221 induces the differentiation.

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

Nonclassical monocytes are specifically depleted following M-CSFR inhibition and these cells are highest in PD-L1 expression in blood of mice during therapy.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

Effects of SC144 on in vivo ovarian tumor.

Depletion of T cells, in particular CD8+ T cells, significantly abrogates HEV neogenesis in tumors. Depletion of T cells, in particular CD8+ T cells, significantly.

Immunologic responses after the MN-mediated cancer immunotherapy.

Macrophage-specific ablation of Vegfa in PyMT implant tumors blocks blood vessel permeability and tumor cell intravasation at the TMEM. A and C, immunofluorescence.

IL32 prompts cell activation and cancer-related pathways.

Tregs and APC subsets in TDLNs of patients with cervical cancer.

Cytotoxic therapy induces CSF1-dependent macrophage recruitment.

Inhibition of VEGFA or macrophage-specific ablation of Vegfa from TIE2hi/VEGFAhi TMEM macrophages reduces vascular permeability and tumor cell intravasation.

Fig. 3. VEGFR-3 signaling increases infiltration of naïve T cells in a CCR7-dependent manner. VEGFR-3 signaling increases infiltration of naïve T cells.

mpJX-594 effects on tumor burden and leukocyte influx.

Quantification of MHC-I, β2m, and T-cell subsets.

Activity of MAC-321 (i. v. and p. o

A: Total collagen content by Sirius red staining in cardiac tissue of control (SD) animals. A: Total collagen content by Sirius red staining in cardiac.

Box plot of acquisition times across the various study cohorts.

SW fraction induces S phase arrest and apoptosis.

Apoptosis induced by ssHHT in HL60 and its derivative, the HL60/MRP, cells. Apoptosis induced by ssHHT in HL60 and its derivative, the HL60/MRP, cells.

Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal tumors. Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal.

Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell depletion. Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell.

Effects of PS-341 on apoptosis in orthotopic human pancreatic tumors.

CLIC1 promotes tumor cell spreading through effects on MLCK

Skin tumor size following ligand activation of PPARβ/δ and inhibition of COX2. Skin tumor size following ligand activation of PPARβ/δ and inhibition of.

Change in antibody-dependent cellular cytotoxicity between baseline and day 15, day 30, and day 45 for cohort 1 and 2 versus cohort 3. Change in antibody-dependent.

Effects of knockdown of ANRIL on NSCLC cell cycle and apoptosis in vitro. Effects of knockdown of ANRIL on NSCLC cell cycle and apoptosis in vitro. A,

GS87 demonstrates efficacy in a circulating AML mouse model system.

coTCRcys-transduced T cells control tumor growth in vivo.

Tlr4−/− attenuates symptomatic parameters of gut toxicity: diarrhea and weight loss. Tlr4−/− attenuates symptomatic parameters of gut toxicity: diarrhea.

Simulations to guide drug design strategies for anti–Bcl-2 therapy.

Cytokine expression in the ileum and colon.

PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant.

Accelerated metastasis spread in tumor-bearing mice treated with paclitaxel and anakinra. Accelerated metastasis spread in tumor-bearing mice treated with.

In vivo thrombosis of tumor vasculature.

Depletion of HDAC2 sensitizes cells to epirubicin-induced apoptosis.

Tumors treated with anti-Flk-1 mAb have increased tumor cell apoptosis, reduced tumor cell proliferation, and increased tumor necrosis. s.c. Tumors treated.

Cisplatin plus PTUPB decreases proliferation and angiogenesis but increases apoptosis as determined by immunohistochemical (IHC) analysis. Cisplatin plus.

Bcl-2 and caspase inhibition fails to inhibit BAMLET-induced cytotoxicity in MCF-7 cells. Bcl-2 and caspase inhibition fails to inhibit BAMLET-induced.

DNA damage-induced RPA foci in asynchronous cells labeled with BUdR.

Angiogenesis in tumors formed by cells varying in the expression of CXCR2. Angiogenesis in tumors formed by cells varying in the expression of CXCR2. A,

Curcumin enhances effects of bortezomib to inhibit angiogenesis in multiple myeloma tumor samples. Curcumin enhances effects of bortezomib to inhibit angiogenesis.

T-cell activation and induction of apoptosis in epithelial cells of oral lesions induced by 4-NQO. T-cell activation and induction of apoptosis in epithelial.

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

Binding and antiproliferative effects of ANG4043 and anti-HER2 mAbs on tumor cells. Binding and antiproliferative effects of ANG4043 and anti-HER2 mAbs.

CLIC1 is upregulated in invadopodia of fibrin-embedded tumor and endothelial cells. CLIC1 is upregulated in invadopodia of fibrin-embedded tumor and endothelial.

Xenograft regrowth studies.

M-CSFR inhibition decreases tumor-associated macrophages in mesothelioma and improves the DC therapy induced CD8+ T-cell phenotype. M-CSFR inhibition decreases.

A, P causes G2-M arrest with apoptosis in asynchronous population of PC-3 when exposed to 1.5 and 5 μmol/L P for various time points. A, P

Ketogenic diets combined with fractionated radiation treatment results in decreased immunoreactive PCNA in tumor tissue. Ketogenic diets combined with.

Quantification of TUNEL staining and OS length among the rab11a constructs. Quantification of TUNEL staining and OS length among the rab11a constructs.

Neutralization of CSF1 and Ad5-HRG treatment.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

CRA inhibits the growth of human tumor xenografts in vivo.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

Immunohistochemical staining for FOXO3a of breast cancer tumor tissues

HMQ1611 inhibited breast tumor growth in mice.

Β-catenin knockout inhibits synovial sarcoma (SS) tumor growth in SYT–SSX2 transgenic mice. β-catenin knockout inhibits synovial sarcoma (SS) tumor growth.

The CD8+ cytotoxic T-cell response in Ron TK−/− hosts in response to tumors is necessary and sufficient to block metastasis. The CD8+ cytotoxic T-cell.

Mice treated with DC therapy and/or M-CSFR inhibition were protected from tumor rechallenge with combination therapy-treated mice displaying superior recall.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

TAMs directly contribute to tumor hypoxia.

GATA-3 immunostaining was scored semiquantitatively; tumors with

A, VEGFR2 staining in the tumor rim and center.

PDL192 and inhibit the growth of xenograft tumors.

GCS-100 selectively kills KRAS-addicted lung tumors.

PEGPH20 depletes HA and decompresses intratumoral vessels.

Treatment with octyl-D-2-HG and octyl-L-2-HG reduces MIR148A expression. Treatment with octyl-D-2-HG and octyl-L-2-HG reduces MIR148A expression. A, Treatment.

Presentation transcript:

Regorafenib inhibits angiogenesis and induces apoptosis. Regorafenib inhibits angiogenesis and induces apoptosis. A, quantification of VEGFR2+/CD31 reveals the strongest decrease in the angiogenic activity in the regorafenib-treated tumors, showing a significant decrease on day 11 (*, P < 0.05; n = 4) and 14 postimplantation (**, P < 0.01; n = 6) compared with the vehicle-treated animals. DC101 significantly reduces the angiogenic activity compared with the controls on day 14 postimplantation (**, P < 0.01; n = 6). B, representative immunostainings of tumors on day 14 postimplantation; CD31 (green), VEGFR2 (red), nuclei (blue); bar, 50 μm. C, further quantification of TIE2+/CD31 shows the lowest ratio in regorafenib-treated tumors on day 14 postimplantation. D, representative immunostainings of tumors on day 14 postimplantation; CD31 (green), TIE2 (red), nuclei (blue); bar, 50 μm. E, quantification of the TUNEL-positive area fraction shows the highest increase in apoptosis in the regorafenib-treated tumors on day 14 postimplantation (**, P < 0.01). F, representative immunostainings of tumors on day 14 postimplantation; CD31 (green), TUNEL (red), nuclei (blue); bar, 50 μm. N, necrotic/apoptotic areas. Data are presented as median ± interquartile range. Lotfi Abou-Elkacem et al. Mol Cancer Ther 2013;12:1322-1331 ©2013 by American Association for Cancer Research